How Large AI Models Accelerate Drug Discovery: Key Stages and Implementation Paths

1. Introduction: AI in Pharma Is Reshaping R&D Paradigms

Traditional drug development typically takes over ten years and costs billions of dollars. Large-model-driven drug discovery is shifting AI from a mere “efficiency tool” to a “core engine” in the R&D pipeline. From AI-assisted molecular generation to large-model-supported clinical trial design, the industry is no longer satisfied with AI simply “making suggestions”—it is exploring AI’s participation in decision-making and even autonomous project advancement.

This article adopts a developer’s perspective to break down the implementation logic, technology choices, and risk boundaries of large models at each key stage of drug development, offering actionable guidance for practitioners.

2. How Do Large Models Land in Each Stage of Drug Discovery?

2.1 Generating Candidate Drug Molecules

Molecular design is the starting point of AI-driven pharma. Traditional high-throughput screening (HTS) has limited efficiency. The current mainstream approach relies on molecular graph neural networks (GNNs) or diffusion models pre-trained on vast chemical literature and patent data to learn structure–activity relationships (SAR) and generate novel molecules.

The specific workflow includes:

• Model selection: SE(3)-equivariant diffusion models or autoregressive Transformers based on 3D structures, fine-tuned on domain-specific datasets containing millions of molecules.
• Generation strategy: Using target protein binding pocket features as conditional input, the model simultaneously optimizes multiple dimensions—activity, selectivity, metabolic stability, and toxicity—and outputs candidate scaffolds that satisfy Lipinski’s Rule of Five.

Publicly reported data indicate that, in certain target scenarios, AI-assisted screening achieves significantly higher in vitro hit rates than random screening, and molecular design iteration cycles can shrink from months to weeks. However, these results depend on experimental conditions and target types, and wet-lab validation remains essential.

2.2 Optimizing Antibody Engineering and Screening

Antibody drugs are a major direction in biopharma. Large models apply across the following technical chain:

• Sequence design tools: Tools such as ProteinMPNN and RFdiffusion can design or optimize complementarity-determining region (CDR) sequences based on antigen epitope information to improve binding affinity.
• Function-driven design: For example, in food allergy treatment, the goal is to completely strip IgE from immune cell surfaces. Models translate this functional objective into design parameters, generating tens of thousands of candidate sequences in a short time.
• Computation-first screening: AI pre-filters candidates, reducing the experimental validation scope from tens of thousands to hundreds and accelerating iteration. A public case study shows a research team testing over a thousand variants in roughly ten weeks and identifying candidates that outperformed existing benchmarks.

Dimension	Traditional Approach	AI-Assisted Approach
Screening cycle	6–12 months	Weeks to two months
Initial candidate pool	Tens of thousands (full experimental)	Tens of thousands generated → hundreds validated
Primary bottleneck	High experimental cost	Wet-lab validation still required

2.3 Improving Genetic Instruction Efficiency for Cell Therapies

Take CAR-T therapy as an example. Traditionally, manually designed genetic instruction fragments often lead to problems such as excessive length, low expression, and short activity duration. Large models optimize through structural compression while preserving function, shortening sequences without compromising tumor-killing capability.

A publicly reported study found that optimized instruction fragments were shortened by approximately 70%, and immune cell surface receptor expression increased roughly tenfold. These specific figures vary by experimental system and should be verified against the original literature. This opens a new path for extending CAR-T from hematological cancers to solid tumors.

2.4 Accelerating Manufacturing Document Review and Regulatory Filing

From preclinical stages to New Drug Applications (NDA/BLA), enormous volumes of technical documentation must be prepared. Large models can:

• Consistency checking: Automatically compare multiple document versions and identify data contradictions.
• Compliance pre-review: Perform preliminary checks against regulatory knowledge bases to reduce the risk of review delays.
• Multi-language adaptation: Assist with translation and formatting for different regulatory jurisdictions.

While this stage does not directly produce new molecules, it has a significant leverage effect on overall R&D timelines.

2.5 Assisting Clinical Trial Planning

Clinical trials are the most expensive phase. Large models can support protocol design and operational coordination. Important disclaimer: AI-assisted protocol design is for reference only. Final approval must come from clinical experts and ethics committees; AI cannot replace medical decision-making. Specific applications include:

• Protocol optimization: Using historical data from similar indications to assist in designing dose gradients and inclusion/exclusion criteria.
• Operations management: Coordinating multi-site contracts and schedules, freeing up research capacity.

3. From Assistance to Autonomy: Practice and Risk Warnings

The case information below has been anonymized and is sourced from public reports. According to reports, a micro biotech company run by a single individual used large models to coordinate more than ten external laboratories and advanced a rare-disease candidate therapy from concept to animal testing in under 18 months. Its technical foundation included: using code-generation interfaces to control lab management systems and form automated workflows; multi-round reasoning to decompose vague goals into executable sub-tasks; and continuous participation in R&D to create a knowledge feedback loop.

However, the boundaries of AI autonomous decision-making in human clinical settings, as well as questions of liability, still require a clear institutional framework. Such practices remain exploratory and should not be treated as established paradigms.

4. Technical Challenges and Response Directions

• Data quality and bias: Strict data governance and validation mechanisms are needed. Current research directions include active learning and data augmentation.
• Insufficient interpretability: Developing explainable AI (XAI) techniques is critical—such as attention visualization and rule extraction.
• Wet-lab bottlenecks: Promoting automated laboratory–AI collaboration and building high-throughput validation platforms.
• Ethics and compliance: The industry and regulators urgently need to jointly establish responsibility frameworks and entry standards for AI in pharma.

5. Conclusion: Three Key Competencies for Developers

The penetration of large models into drug development represents a systemic reconstruction of R&D paradigms, not a simple replacement of human labor. For developers, we recommend focusing on three competencies:

1. Understand model selection and fine-tuning logic for scenarios like molecular generation and antibody design.
2. Master experimental data processing, workflow orchestration, and automation toolchain construction.
3. Familiarize yourself with drug development compliance and ethical requirements, and uphold safety boundaries in technical applications.

Only by combining model capabilities with scientific literacy can practitioners truly participate in this AI-driven transformation of the pharmaceutical industry.